£17.0M
The financing round was backed by Bayland Capital and founding shareholder CN Innovations to accelerate product development and commercial expansion.
CN Bio
CN Bio develops advanced Organ-on-a-Chip systems to transform human-relevant drug discovery.
£17.0MTotal raised
CN Bio is a leading provider of single-organ and multi-organ microphysiological systems designed to improve preclinical drug discovery. The company delivers advanced Organ-on-a-Chip solutions that reduce reliance on animal models and provide human-relevant data.
Categories
Team
Paul Brooks
CEO
Paul serves as chief executive officer at CN Bio, following leadership roles at Horizon Discovery, Abcam, OXGENE, and MilliporeSigma.
LinkedIn